There are currently 443 active clinical trials seeking participants for Breast Cancer research studies. The states with the highest number of trials for Breast Cancer participants are California, Ohio, Illinois and Michigan.
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
NCT05150652
Recruiting
The goal of this study is to access whether treatment of early state estrogen-rich breast cancers with neoadjuvant endocrine therapy will result in higher rates of margin negativity on lumpectomy specimen.
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
03/25/2025
Locations: University of Kentucky Markey Cancer Center, Lexington, Kentucky
Conditions: Breast Cancer, HER2-negative Breast Cancer, Node-negative Breast Cancer, Breast Carcinoma
Register for Updates
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
NCT05483491
Recruiting
This is a phase I clinical trial to determine the maximum tolerated dose (MTD) of KK-LC-1 TCR-T cells for the treatment of metastatic cancers that express KK-LC-1. Participants will receive a conditioning regimen, KK-LC-1 TCR-T cells, and aldesleukin. The safety profile and clinical response to treatment will be determined.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey +1 locations
Conditions: Gastric Cancer, Breast Cancer, Cervical Cancer, Lung Cancer
Register for Updates
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
NCT06401421
Recruiting
The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Katmai Oncology Group - Anchorage, Anchorage, Alaska +36 locations
Conditions: Breast Cancer
Register for Updates
Evaluating a Physical Activity Index for Assessment and Counseling for Breast and Colon Cancer Survivors
NCT06340503
Recruiting
The purpose of this research study is to determine whether using the physical activity index screener, exercise coaching, and self-monitoring will increase physical activity and reduce time spent sitting or being inactive in patients who had breast or colon cancer.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/25/2025
Locations: Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina
Conditions: Breast Cancer, Colon Cancer
Register for Updates
Longitudinal Sexual and Reproductive Health Study of Women with Breast Cancer and Lymphoma
NCT01788839
Recruiting
The purpose of this study is to see how cancer treatment affects sexual and reproductive function. The patient will also be asked to participate in blood draws to see if and how cancer treatment affects the ovaries and the ability to have children (fertility). These blood draws are optional and the patient can still participate in the questionnaire portion of the study even if they choose not to have their blood drawn.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +6 locations
Conditions: Breast Cancer, Lymphoma, Hodgkin's Lymphoma
Register for Updates
Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
NCT06169371
Recruiting
This is a post-marketing single arm, phase IV trial in which patients with high-risk early-stage HR+HER2- breast cancer will receive adjuvant abemaciclib in combination with endocrine therapy (ET) After study intervention, participants will remain on combination abemaciclib + ET at the discretion of their treating providers
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: University of Illinois, Chicago, Illinois +1 locations
Conditions: Breast Cancer
Register for Updates
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT05950945
Recruiting
This study will evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who are both hormone receptor \[HR\]-negative and HR-positive) unresectable and/or metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Mount Sinai Medical Center, Miami Beach, Florida +69 locations
Conditions: Breast Cancer
Register for Updates
Breast Cancer, Reasoning, and Activity Intervention
NCT04816006
Recruiting
This phase II trial tests whether an exercise intervention works to improve cognitive function in breast cancer survivors. Many breast cancer survivors report cancer-related cognitive impairment, which this has recently become a priority in clinical research due to its dramatic impact on daily functioning, quality of life, and long-term health. Aerobic exercise has the potential to improve cognitive function and brain health in older adults and is recommended as a safe, tolerable, and accessible... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Breast Cancer, Breast Neoplasms, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Cancer-related Cognitive Dysfunction
Register for Updates
MRg-NIRS Imaging System Breast Cancer Trial
NCT06400563
Recruiting
This trial is a study of 20 women with breast cancer to evaluate the addition of MR-guided (MRg) near-infrared spectroscopy (NIRS) with and without contrast, as part of a program to improve clinical management of women receiving breast magnetic resonance imaging (MRI).
Gender:
FEMALE
Ages:
Between 18 years and 83 years
Trial Updated:
03/24/2025
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Breast Cancer
Register for Updates
Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
NCT06902311
Recruiting
This study evaluates the rates of radiation-specific toxicity, quality of life, and oncologic outcomes for early-stage breast cancer and ductal carcinoma in situ treated with 5-fraction whole breast irradiation (WBI) with a simultaneous integrated tumor bed boost (SIB). SIB refers to the technique tumor bed boost given at the same time as standard radiation therapy. The FAST-Forward trial previously showed that a 1-week course of radiotherapy had similar effects to the traditional 3-week course... Read More
Gender:
FEMALE
Ages:
50 years and above
Trial Updated:
03/24/2025
Locations: University of North Carolina, Chapel Hill, North Carolina
Conditions: Breast Cancer, Early-stage Breast Cancer, Ductal Carcinoma in Situ, DCIS
Register for Updates
Repurposing Riluzole for Cancer-Related Cognitive Impairment: a Pilot Trial
NCT06580002
Recruiting
This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels of breast cancer survivors with cancer related cognitive impairment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California
Conditions: Breast Cancer
Register for Updates
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT02830724
Recruiting
Background: In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person. This is called gene transfer. For this study, researchers will modify the person s white blood cells with anti-CD70. Objectives: To see if a gene transfer with anti-CD70 cells can safely shrink tumors and to be certain the treatment is safe. Eligibility: Adults age 18... Read More
Gender:
ALL
Ages:
Between 18 years and 72 years
Trial Updated:
03/22/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Pancreatic Cancer, Renal Cell Cancer, Breast Cancer, Melanoma, Ovarian Cancer
Register for Updates